Editor’s observe: A livestream of the occasion can be embedded beneath at 1 p.m. ET.
Since the event of Gleevec twenty years in the past, precision most cancers medicines have develop into a driving power in biotech and a supply of hope for most cancers sufferers.
Be part of STAT’s Adam Feuerstein and our panel of consultants as they focus on what has labored finest, what hasn’t, and the most popular new approaches in precision most cancers medicines, together with antibody drug conjugates, tyrosine kinase inhibitors, and extra.
Sponsor introduction:
- Axel Hoos, M.D., Ph.D., chief government officer, Scorpion Therapeutics
Featured audio system:
- Patricia M. LoRusso, DO, Ph.D. (hc), president-elect, American Affiliation for Most cancers Analysis (AACR)
- Vivek Subbiah, M.D., chief, early-phase drug growth, Sarah Cannon Analysis Institute
- Suresh S. Ramalingam, M.D., FACP, FASCO, government director, Winship Most cancers Institute of Emory College; affiliate vp for most cancers, Woodruff Well being Sciences Middle; Roberto C. Goizueta Chair for Most cancers Analysis
- Adam Feuerstein, senior author, biotech, STAT (moderator)
